Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Moligo Technologies AB is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, which requires the company to maintain a broader prosecution strategy. Dealing with 2 distinct examiners means the applicant must adapt to different individual styles and interpretations of patent law. The involvement of 2 distinct art units further suggests that the technical scope of these filings may span different sub-specialties within the Biotechnology & Pharmaceuticals field, necessitating a broader legal strategy to address varying examination standards.
ROBERT J YAMASAKI is the busiest examiner for the company, currently holding 1 pending office action. This accounts for 1 of the 2 pending office actions currently active in the portfolio. Because the prosecution involves the various art units, the company's legal team must be prepared for varying technical standards that may apply to different aspects of their innovations. The lack of concentration under a single examiner suggests a range of technical filings that necessitate a case-specific approach to each of the pending matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YAMASAKI, ROBERT J | 1 | 67.4% | +44.1% |
| POHNERT, STEVEN C | 1 | 12.5% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17801794 | METHOD AND PRODUCTS FOR PRODUCING SINGLE STRANDED DNA POLYNUCLEOTIDES | YAMASAKI, ROBERT J | — |
| 17428889 | METHOD AND PRODUCTS FOR PRODUCING FUNCTIONALIZED SINGLE STRANDED OLIGONUCLEOTIDES | POHNERT, STEVEN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17801794 | METHOD AND PRODUCTS FOR PRODUCING SINGLE STRANDED DNA POLYNUCLEOTIDES | YAMASAKI, ROBERT J | — |
| 17428889 | METHOD AND PRODUCTS FOR PRODUCING FUNCTIONALIZED SINGLE STRANDED OLIGONUCLEOTIDES | POHNERT, STEVEN C | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17801794 | METHOD AND PRODUCTS FOR PRODUCING SINGLE STRANDED DNA POLYNUCLEOTIDES | YAMASAKI, ROBERT J | 1657 | §102§103 | Non-Final OA | — | Pending | Aug 24, 2022 |
| 17428889 | METHOD AND PRODUCTS FOR PRODUCING FUNCTIONALIZED SINGLE STRANDED OLIGONUCLEOTIDES | POHNERT, STEVEN C | 1683 | §103 | Non-Final OA | — | Pending | Aug 05, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMoligo Technologies AB has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Robert J Yamasaki has the most, with 1 of Moligo Technologies AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
